Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 587-595

  Wang Johanning, Feng ^a,b,c   Li, Ming ^a,c   Esteva, Francisco J ^b   Hess, Kenneth R ^b   Yin, Bingnan ^d   Rycaj, Kiera ^b   Plummer, Joshua B ^a,c   Garza, Jeremy G ^a   Ambs, Stefan ^e   Johanning, Gary L ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

biomarkers; breast cancer; early detection; endogenous retroviruses; HERV K; metastasis

Indexed keywords

BIOLOGICAL MARKER; HUMAN ENDOGENOUS RETROVIRUS TYPE K ANTIBODY; MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CONTROLLED STUDY; EARLY CANCER; ENDOGENOUS RETROVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; HUMAN; HUMAN ENDOGENOUS RETROVIRUS TYPE K GENE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; METASTASIS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR INVASION; VIRUS GENE; VIRUS REACTIVATION;

EID: 84888008517     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28389     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. Cancer J Clin 2012; 62: 10-29.
2. Viale G,. Histopathology of primary breast cancer 2005. Breast 2005; 14: 487-92.
3. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441-52.
4. Virnig BA, Wang SY, Shamilyan T, et al. Ductal carcinoma in situ: risk factors and impact of screening. J Natl Cancer Inst Monogr 2010; 2010: 113-6.
5. Kuerer HM, Lari SA, Arun BK, et al. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 2012; 133: 1131-41.
6. Lari SA, Kuerer HM,. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2011; 2: 232-61.
7. Buscher K, Trefzer U, Hofmann M, et al. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 2005; 65: 4172-80.
8. Ryan FP,. Human endogenous retroviruses in health and disease: a symbiotic perspective. J Roy Soc Med 2004; 97: 560-5.
9. Seifarth W, Skladny H, Kriegschneider F, et al. Retrovirus-like particles released from the human breast-cancer cell-line T47-D display type-B-related and type-C-related endogenous retroviral sequences. J Virol 1995; 69: 6408-16.
10. Etkind PR, Lumb K, Du J, et al. Type 1 HERV-K genome is spliced into subgenomic transcripts in the human breast tumor cell line T47D. Virology 1997; 234: 304-8.
11. Wang-Johanning F, Radvanyi L, Rycaj K, et al. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res 2008; 68: 5869-77.
12. Wang-Johanning F, Frost AR, Johanning GL, et al. Expression of human endogenous retrovirus K envelope transcripts in human breast cancer. Clin Cancer Res 2001; 7: 1553-60.
13. Wang-Johanning F, Rycaj K, Plummer JB, et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 2012; 104: 189-210.
14. Wang-Johanning F, Frost AR, Jian BX, et al. Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene 2003; 22: 1528-35.
15. Subramanian RP, Wildschutte JH, Russo C, et al. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology 2011; 8: 90.
16. Wang-Johanning F, Gillespie GY, Grim J, et al. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects. Cancer Res 1998; 58: 1893-900.
17. Wang-Johanning F, Frost AR, Jian B, et al. Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma. Cancer 2003; 98: 187-97.
18. de Parseval N, Lazar V, Casella JF, et al. Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins. J Virol 2003; 77: 10414-22.
19. Wang-Johanning F, Lu DW, Wang YY, et al. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002; 94: 2199-210.
20. Chlebowski RT, Anderson G, Manson JE, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 2010; 28: 2690-7.
21. Armbruester V, Sauter M, Krautkraemer E, et al. A novel gene from the human endogenous retrovirus K expressed in transformed cells. Clin Cancer Res 2002; 8: 1800-7.
22. Denne M, Sauter M, Armbruester V, et al. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol 2007; 81: 5607-16.
23. Kleiman A, Senyuta N, Tryakin A, et al. Herv-K(HML-2) Gag/Env antibodies as indicator for therapy effect in patients with germ cell tumors. Int J Cancer 2004; 110: 459-61.
24. Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008; 113: 1294-301.
25. Baek JM, Jin QR, Ensor J, et al. Serum CD44 levels and overall survival in patients with HER2-positive breast cancer. Breast Cancer Res Treat 2011; 130: 1029-36.
26. Shen YF, Tolic N, Liu T, et al. Blood peptidome-degradome profile of breast cancer. PLoS One 2010; 5: e13133.
27. Padler-Karavani V, Hurtado-Ziola N, Pu MY, et al. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res 2011; 71: 3352-63.
28. Anderson KS, Sibani S, Wallstrom G, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011; 10: 85-96.
29. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18: 868-73.
30. Pichon JP, Bonnaud B, Cleuziat P, et al. Multiplex degenerate PCR coupled with an oligo sorbent array for human endogenous retrovirus expression profiling. Nucleic Acids Res 2006; 34: e46.
31. Lu H, Ladd J, Feng Z, et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) 2012; 5: 1036-43.
32. Esteva FJ, Sahin AA, Cristofanilli M, et al. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 2002; 12: 319-28.